University of Nevada, Las Vegas at CTAD 2026

Nov 16–19, 2026 Boston, MA ~1.7k attendees Website

University of Nevada, Las Vegas takes part in 4 sessions at CTAD 2026 in Boston. Its program spans new drug mechanisms and treatment of psychosis in Alzheimer's disease. Its work covers new molecules in phase 2b, a TREM2 agonist trial and psychosis results with remlifanserin and KarXT.

OrganizationCTAD 2026 Attendance
Poster
Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue
Talk
Mon Nov 16
3:25pm–3:50pm
New Molecules in Phase 2b – Proof of Concept and Beyond
Trial design and endpoints · with IHU HealthAge
Talk
Tue Nov 17
9:35am
Talk
Wed Nov 18
9:00am

Explore the full CTAD 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Boston. Leave your work email and we’ll be in touch.

Privacy

Download the full CTAD 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from University of Nevada, Las Vegas

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction